Presentation on theme: "Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014"— Presentation transcript:
Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
1) terminology of hep C 2) benefits of hep C treatment 3)drug interaction issues with HIV meds My thanks to my colleague Debika Bhattacharya for use of her slides for this presentation.
Hep C viral load is not the same as HIV viral load ◦ Hep C viral load does not correlate with risk of death, cirrhosis, liver damage.
Hep C can be cured with current medications, unlike HIV. ◦ Cure=SVR “sustained virological response” ◦ Hep C viral load 6 months after completing treatment is undetectable = SVR
CHILD score: A, B or C.(also scored numerically:5 or more points) ◦ Risk of death from cirrhosis. ◦ Only to be used in patients with documented cirrhosis ◦ Important since simeprevir contraindicated in patients with CHILD score>5.(or B or C) ◦ Website for calculator for CHILD score: ◦ :http://www.mdcalc.com/child-pugh-score-for- cirrhosis-mortality/
Patients who do develop cirrhosis have many problems: ◦ Esophageal varices and recurrent internal bleeding ◦ Ascites (fluid on the abdomen) ◦ Brain damage from hepatic encephalopathy ◦ liver cancer ◦ Problems with medications ◦ Leg edema ◦ Jaundice
Even without cirrhosis, there are complications of hep C ◦ Fatigue ◦ Cryoglobulimia (kidney damage) ◦ Porphyria cutanea tarda ◦ Increased risk of diabetes
Treatment of hep C reduces or eliminates risk of liver cancer, cirrhosis, cryoglobulinia, and porphyria. However, cirrhosis is permanent scarring, so once there is cirrhosis, there is always some risk of liver cancer in the future, even if hep C cured. Treatment of hepatitis C also appears to alleviate fatigue. Hepatology.2014 Apr 5
Overall <5% of study subjects stopped sofosbuvir and simeprevir on the COSMOS and other studies because of side effects.
Daclatasvir: effective against genotypes 1,2,3 Ledipasvir: effective against genotype 1; to be combined with sofosbuvir into 1 pill a day
find those patients who need to be treated NOW with simeprevir/sofosbuvir, and who are willing to be on a limited HIV regimen (complera, isentress, truvada) in order to prevent drug interactions Patients who are on Atripla, Stribild, or boosted protease inhibitors will have to wait until more hep C drugs available.
Treat HIV first if CD4 <500 and get HIV viral load <50 copies for maximal response from hep C meds If CD4 count >500, may be able to wait on starting HIV meds until after hep C treatment completed.
Obtain baseline hep C viral load (within 3 months of beginning treatment) Counsel patient on need to take all meds Counsel patient on need to avoid sunlight, risks of nausea and rash Alter patient’s HIV regimen if necessary.
Follow-up 2 weeks and at 4 week point after initiating hep C meds to check on adherence and immediate side effects. Mild rash can be treated through with benedryl, topical steroids Check CBC, platelets, AST, ALT every 2 weeks during first 4 weeks. Repeat Hep C viral load at Week 4 point
Hep C viral load should be <25 copies at Week 4 point; if not, patient may need to be discontinued to prevent resistance. Recheck hep c viral load at Week 8. If hep c meds tolerated, see patient at Week 4, Week 8 and Week 12 and check CBC, platelets, AST, and ALT at each visit(or monthly if being treated x 24 weeks)
If patient on ribavirin containing regimen, dose reduce ribavirin if anemia develops: Hb < 10 Most anemia with Sof/ribavirin mild.
Repeat Hep C viral load 6 months after completing therapy to ascertain cure: “SVR”.
1)hep C viral load of 2,000 copies may be a patient undergoing self-cure 2)a patient who is cured of hep C but still has cirrhosis has no risk of liver cancer 3)simeprevir has multiple drug interactions with many HIV medications 4)patients cured of hep C have less fatigue
191 MSM with cured (treated with meds) or spontaneously cleared hep C ◦ 44 were reinfected ◦ 8 were infected several more times ◦ Same or different genotypes ◦ None had IDU risk factor ◦ Estimated that 25% will be re-infected within 2 years of cure. ◦ AIDS 2013 Oct 23;27(16):2551-7
Prison populations in Spain: ◦ 119 Hep C Ab+, cured or spontaneously cleared while as inmate. 81% hx of IDU ◦ Reinfection rate 5.37 per 100 person years, higher in active IDU and HIV co-infected ◦ J Hepatology July;59(1):45-51
Selection of patients for hep C treatment will have to include safe sex counseling and sobriety
Interferon free hep C drugs are here, and more coming Be prepared for elaborate PA process to get the meds Treatment will reduce complications of hep C infection and improve quality of life Select patients who are not likely to get re- infected and will adhere to frequent clinic visits during treatment.